Volume 368, Issue 9541, Pages (September 2006)

Slides:

Advertisements

Similar presentations

Slide Source: Primary and Other Outcomes: DREAM Rosiglitazone group (n=2635) Placebo group (n=2634)HR (95% CI)p Composite primary.

Advertisements

1 Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled.

Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of.

Volume 355, Issue 9212, Pages (April 2000)

Volume 384, Issue 9961, Pages (December 2014)

Volume 352, Issue 9131, Pages (September 1998)

Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes.

Volume 380, Issue 9846, Pages (September 2012)

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive.

Volume 367, Issue 9517, Pages (April 2006)

Volume 359, Issue 9322, Pages (June 2002)

Association between hyperglycaemia and adverse perinatal outcomes in south Asian and white British women: analysis of data from the Born in Bradford cohort

Volume 14, Issue 10, Pages (September 2013)

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Figure 1. Consort flow diagram.

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331 288.

Volume 376, Issue 9734, Pages (July 2010)

Volume 373, Issue 9679, Pages (June 2009)

Diabetes and Pregnancy

Body-mass index, abdominal adiposity, and cardiovascular risk

Meta-analysis of randomised controlled trials

Volume 376, Issue 9734, Pages (July 2010)

Volume 375, Issue 9709, Pages (January 2010)

Physical activity and prevention of type 2 diabetes

Volume 392, Issue 10145, Pages (August 2018)

Body-mass index and all-cause mortality – Authors' reply

Volume 382, Issue 9891, Pages (August 2013)

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Aspirin in the prevention of cancer – Author's reply

Increased body-mass index in patients with narcolepsy

A randomized controlled trial of a web-based education intervention for women with gestational diabetes mellitus Mary Carolan-Olah, Padaphet Sayakhot

Volume 373, Issue 9679, Pages (June 2009)

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta- analysis of individual participant data from randomised trials

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Body-mass index and all-cause mortality – Authors' reply

Incident diabetes in clinical trials of antihypertensive drugs

Volume 9, Issue 9, Pages (September 2010)

Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies

Volume 378, Issue 9801, Pages (October 2011)

Socioeconomic inequalities in childhood and adolescent body-mass index, weight, and height from 1953 to 2015: an analysis of four longitudinal, observational,

Volume 375, Issue 9732, Pages (June 2010)

Volume 379, Issue 9822, Pages (March 2012)

Prediabetes in youths: mechanisms and biomarkers

The Stunned β Cell: A Brief History

Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled.

Volume 14, Issue 9, Pages (September 2015)

Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: a post-hoc analysis of the longitudinal Whitehall.

Volume 372, Issue 9647, Pages (October 2008)

Volume 371, Issue 9627, Pages (May 2008)

Telling it like it isn't: truth and lies in a post-9/11 world

Association between adiposity outcomes and residential density: a full-data, cross- sectional analysis of 419 562 UK Biobank adult participants Dr Chinmoy.

C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study Heart Protection.

Volume 377, Issue 9771, Pages (March 2011)

Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331 288.

Volume 14, Issue 10, Pages (September 2013)

Department of Error The Lancet Volume 369, Issue 9564, (March 2007)

Low-technology approaches

Association between hyperglycaemia and adverse perinatal outcomes in south Asian and white British women: analysis of data from the Born in Bradford cohort

Volume 379, Issue 9822, Pages (March 2012)

ACST: which subgroups will benefit most from carotid endarterectomy?

Medically unexplained symptom management

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Volume 11, Issue 3, Pages (March 2010)

Volume 383, Issue 9921, Pages (March 2014)

Volume 14, Issue 9, Pages (September 2015)

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28.

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

Clinic attendance and disengagement of young adults with type 1 diabetes after transition of care from paediatric to adult services (TrACeD): a randomised,

Presentation transcript:

Volume 368, Issue 9541, Pages 1096-1105 (September 2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial The Lancet Volume 368, Issue 9541, Pages 1096-1105 (September 2006) DOI: 10.1016/S0140-6736(06)69420-8 Copyright © 2006 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile Data were censored at time of last follow-up for all participants. The Lancet 2006 368, 1096-1105DOI: (10.1016/S0140-6736(06)69420-8) Copyright © 2006 Elsevier Ltd Terms and Conditions

Figure 2 Time to occurrence of primary outcome The Lancet 2006 368, 1096-1105DOI: (10.1016/S0140-6736(06)69420-8) Copyright © 2006 Elsevier Ltd Terms and Conditions

Figure 3 Effect of rosiglitazone on the primary outcome in key subgroups BMI=body-mass index. IIFG=isolated impaired fasting glucose. IIGT=isolated impaired glucose tolerance. WHR=waist-to-hip ratio. The Lancet 2006 368, 1096-1105DOI: (10.1016/S0140-6736(06)69420-8) Copyright © 2006 Elsevier Ltd Terms and Conditions

Figure 4 Proportion of participants who either developed diabetes, regressed to normal, or had impaired fasting glucose or impaired glucose tolerance, or both, at the last assessment (A) FPG defined as concentration <6·1 mmol/L or (B) <5·6 mmol/L. The p value for the likelihood that the distribution across categories would have occurred by chance using both FPG cutoffs was <0·0001. The Lancet 2006 368, 1096-1105DOI: (10.1016/S0140-6736(06)69420-8) Copyright © 2006 Elsevier Ltd Terms and Conditions

Figure 5 Effect of rosiglitazone on the point estimates of (A) fasting plasma glucose (FPG) and (B) 2-h plasma glucose (PG) concentrations The Lancet 2006 368, 1096-1105DOI: (10.1016/S0140-6736(06)69420-8) Copyright © 2006 Elsevier Ltd Terms and Conditions

Figure 6 The effect of rosiglitazone on weight and fat distribution Overall effect of rosiglitazone and placebo on the slope of (A) weight and (B) body-mass index, (C) waist-to-hip ratios in all participants, and (D) waist and hip separately. p values indicate the differences in slope and the markers indicate the mean values for rosiglitazone (square) and placebo (circle) at every time point. Weight, waist, and hip circumference were recorded at baseline, 2 years, and study end (3 or 4 years for most participants). NS=not significant. The Lancet 2006 368, 1096-1105DOI: (10.1016/S0140-6736(06)69420-8) Copyright © 2006 Elsevier Ltd Terms and Conditions